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first evidence for a beneficial effect of additional iTBS on in-
termediate nicotine abstinence; however, the low number of 
iTBS sessions might have prevented longer effects. More 
lasting effects might be achieved by iTBS maintenance ses-
sions in analogy to the treatment of depression. 
 © 2014 S. Karger AG, Basel 
 Introduction 
 Smoking is one of the main risk factors for developing 
cardiovascular problems, cancer and lung diseases  [1–3] , 
which are among the leading causes of mortality world-
wide  [1, 4] . Prevalence of smoking is at about 30% in the 
US and Europe  [4, 5] , morbidity increases with the num-
ber of cigarettes smoked as well as with the number of 
years of smoking  [2, 6] . Importantly, life expectancy has 
been shown to increase up to presmoking levels when 
quitting smoking permanently  [2] . Yet, only a small pro-
portion of smokers succeed in quitting unaided and about 
90% relapse within 1 year  [7, 8] .
 Cognitive-behavioral therapy (CBT), nicotine replace-
ment therapy, and pharmacotherapy (e.g. bupropion, va-
renicline) improve the 1-year success rate up to 35%  [9] . 
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 Abstract 
 Smoking is among the leading causes of mortality world-
wide. Discontinuing smoking can increase life expectancy to 
the presmoking level. Unaided attempts are often ineffec-
tive, strengthening the necessity of cognitive-behavioral 
therapy (CBT), nicotine replacement or pharmacotherapy. 
Still, relapse rates are high. Recently, a modulation of nico-
tine craving, which predicts relapse, through transcranial 
magnetic stimulation to the prefrontal cortex was shown. In 
a pilot study, we investigated whether 4 sessions of intermit-
tent theta burst stimulation (iTBS) as add-on treatment to 
CBT reduces nicotine craving and improves long-term absti-
nence (at 3, 6 and 12 months). Smokers were randomly as-
signed to a treatment (n = 38) or a sham group (n = 36). Al-
though we did not find reduced craving, we could show 
higher abstinence rates in the treatment group at 3 months. 
At 6 and 12 months abstinence rates did not differ signifi-
cantly. Results at 12 months, however, have to be interpret-
ed cautiously due to significant differences in the dropout 
rates between the two groups at this time point. We provide 
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Drugs, however, are frequently accompanied by side ef-
fects, such as nausea, sickness and insomnia  [9] . New ap-
proaches in the field of brain stimulation techniques have 
been investigated as to whether they can improve success 
rates. Pogarell et al.  [10] have shown that repetitive tran-
scranial magnetic stimulation (rTMS) to the prefrontal 
cortex (PFC) effectively stimulates dopamine release in 
the mesolimbic dopaminergic system structures, includ-
ing the ventral tegmentum, the nucleus accumbens and 
parts of the  PFC, which are involved in the perception of 
reward and craving  [11–13] . For a detailed description of 
the molecular and neural processes involved in nicotine 
addiction, withdrawal symptoms and craving, the reader 
is referred to the available literature [e.g.  14–19 ]. More 
specifically, studies indicate a positive modulation of ad-
diction-related behaviors, such as decreased craving or 
consumption following rTMS of the right or left PFC [co-
caine:  20 , alcohol:  21 , nicotine:  22, 23 ] or transcranial di-
rect current stimulation (tDCS) of the bilateral PFC [al-
cohol:  24 , nicotine:  25 ]. A summary of the current litera-
ture is provided by Barr et al.  [26] and Jansen et al.  [27] .
 Intermittent theta burst stimulation (iTBS) is an rTMS 
protocol that is administered at lower intensities and 
shorter intervals, improving its tolerability and safety in 
comparison to conventional rTMS protocols  [28] . It has 
been shown to produce longer-lasting effects than rTMS 
[i.e. up to 60 min after a single session:  29 ]. Given the 
promising findings of rTMS studies concerning addictive 
behavior, iTBS offers another more tolerable option to 
approach nicotine addiction.
 In the present pilot study, we therefore investigated 
whether we could replicate and extend previous TMS/tDCS 
findings of improved immediate abstinence rates and/or 
reduced self-reported craving by administering 4 sessions 
of iTBS to the right dorsolateral PFC (dlPFC), accompany-
ing a well-established CBT. As craving might represent the 
crucial mediating factor in nicotine addiction, we opted for 
right dlPFC stimulation as this area has been found to be 
associated with a reduction of craving. Furthermore, we in-
vestigated the longevity of this effect by following partici-
pants up until 12 months after treatment cessation.
 Methods and Materials 
 Sample 
 Seventy-four smokers (34 female; age 45.46 ± 10.64 years) re-
cruited via advertisements and screened in a telephone interview 
met the inclusion criteria: (1) a Fagerström Test for Nicotine De-
pendence score (FTND)  ≥ 3  [30] and (2) a diagnosis of nicotine 
dependence according to ICD-10: F17.25  [31] . Other past or cur-
rent neurological or mental disorders were excluded via a short 
version of the SCID-I screening questionnaire  [32] . Exclusion cri-
teria followed the Wassermann protocol for a safe TMS applica-
tion  [33] and included previous TMS experience. The study was 
approved by the local ethics committee and all procedures were in 
accordance with the latest version of the Declaration of Helsinki. 
All participants gave written informed consent.
 Study Protocol 
 All participants completed a 3-week group CBT (6 semiweekly 
meetings), i.e. the Würzburg Program for Ambulant Tobacco Dis-
habituation. This program follows the guidelines for smoking ces-
sation promoted by Raw et al.  [34] . Between meetings 2 and 3, 
smoking cessation was scheduled. After that, CBT was accompa-
nied by the iTBS treatment from meeting 3 to 6 (i.e. 4 iTBS ses-
sions). Participants were randomly assigned to the treatment or 
the sham group. Thus, groups differed only with respect to iTBS 
treatment (CBT + iTBS treatment or CBT + sham iTBS). Following 
meeting 6, participants were contacted by phone after 3, 6 and 12 
months to inquire about the abstinence rate (defined here as con-
tinuous abstinence, thus excluding any consumption of cigarettes 
since treatment).
 Questionnaires 
 The FTND  [30] , a questionnaire determining the level of nico-
tine dependence, was administered before the treatment, all other 
questionnaires before (prior to meeting 1) and after treatment (af-
ter meeting 6). The Questionnaire on Smoking Urges (QSU) [35] 
identifies changes in the urge to smoke. The questionnaire of Self-
Efficacy in Smokers (SER) [36] with its subscales confidence and 
temptation assesses the expectation to successfully quit smoking.
 Intermittent Theta Burst Stimulation 
 Four sessions of iTBS (Medtronic MagPro X100, Medtronic 
MagPro, Düsseldorf, Germany) were administered over electrode 
position F4, which, according to the international 10–20 system 
 [37, 38] , is located over the right dlPFC  [39] . The iTBS followed 
the protocols introduced by Huang et al.  [29] , i.e. three pulses of 
stimulation, repeated every 200 ms for 2 s, are given at 50 Hz. These 
TBS trains are repeated every 10 s, totaling 600 pulses (total dura-
tion: 190 s). Prior to stimulation, the individual motor threshold 
(MT) was determined over the left primary motor cortex, which 
did not differ between groups (treatment group: 33.27 ± 4.37; sham 
group: 34.46 ± 5.37). The treatment group was stimulated with a 
figure-of-eight coil (MC-B70, Medtronic MagPro, Düsseldorf, 
Germany) at 80% individual MT, while the sham group was stim-
ulated at 60% individual MT, with the coil being tilted by 45°1. 
Stimulation was administered right before or after CBT meetings 
3–6. Participants were blind with regard to iTBS stimulation, as 
were the respective CBT therapists who did not know the group 
assignment. None of the subjects reported any side effects after 
receiving iTBS.
 1   In a study systematically assessing this sham setup over the motor cortex, 
Loo et al.  [40] could show negligible effects evoking motor-evoked poten-
tials, reducing the measured stimulation level to < 50% at maximal machine 
output. Therefore, although effects cannot be excluded, choosing this kind 
of setup as well as reducing stimulation intensity to 60% MT is unlikely to 
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 Questionnaire data were analyzed by means of analyses of vari-
ance (ANOVA) with the factors ‘group’ (treatment vs. sham) and 
‘time’ (pre vs. post). Abstinence data were analyzed by means of 
contingency table statistics and odds ratios were calculated. Par-
ticipants that could not be contacted via telephone after the treat-
ment (dropouts) were considered relapsing participants2. As we 
had a directional hypothesis based on previous studies administer-
ing rTMS or tDCS to the dlPFC (i.e. a higher abstinence rate in the 
treatment group), hypothesis testing was one-sided. The alpha lev-
el was set at 5%.
 Results 
 Questionnaire Data 
 The two groups did not differ with respect to level of 
addiction (FTND), number of cigarettes per day, years of 
smoking, age at the onset of smoking and number of at-
tempts to quit. See  table 1 for a summary of the sample 
characteristics.
 The 2 × 2 ANOVAs for the other questionnaires yield-
ed significant main effects for time (all p values < 0.001). 
SER scores on ‘confidence of staying abstinent’ increased, 
whereas QSU scores decreased from pre- to posttreat-
ment. Neither significant group effects nor significant 
group-by-time interactions indicating differential treat-
ment effects in the groups were found. See  table 2 for a 
summary of the results.
 Abstinence Data 
 Analyses revealed that for the 3-month follow-up the 
treatment group displayed an increased abstinence rate as 
compared to the sham group, a difference that could not 
be observed after 6 and after 12 months ( table 3 ). Drop-
outs were equally distributed across the groups at 3 
months (χ 2 = 0.85, p = 0.36) and 6 months (χ 2 = 1.30, p = 
0.25), but not at 12 months (χ 2 = 2.90, p = 0.09), where a 
higher dropout rate was seen in the sham group. Thus, the 
12-month findings should be interpreted very cautiously 
and are only given for reasons of completeness. See  ta-
ble 3 for a summary of the results.
 Discussion 
 The current study investigated whether CBT for smok-
ing cessation might benefit from add-on treatment with 
iTBS and revealed a beneficial effect, i.e. a higher absti-
nence rate in the verum as compared to the sham group, 
at 3 months after the end of therapy. This is rather re-
markable given a treatment of only 4 iTBS sessions. At 6 
and 12 months, no lasting beneficial effects of iTBS were 
found, indicating that such a short add-on treatment may 
only be helpful in the short or intermediate term and im-
prove the CBT outcome. For instance, for maintaining 
anti-depressive effects by means of rTMS/TBS, , repeti-
tion of the treatment cycle was found to be crucial for 
longer-lasting effects [e.g.  41, 42 ]. Extending the duration 
of the iTBS sessions or offering booster sessions might 
thus be beneficial in supporting long-term nicotine absti-
nence. In this respect, in a sham-controlled study, Amiaz 
et al.  [22] administered 10 daily rTMS sessions to the left 
dlPFC, which reduced craving and cigarette consumption 
directly afterwards, dissipating eventually, however. Yet 
in a subgroup being stimulated directly after exposure to 
smoking-related cues, a trend towards lower cigarette 
consumption after 6 months was found. Methodological 
differences between Amiaz et al.  [22] and our study great-
ly limit comparability and the drawing of valid conclu-
sions. Besides other protocol differences (rTMS vs. iTBS; 
cue exposure-related vs. -unrelated stimulation; single vs. 
add-on therapy), we stimulated the right dlPFC. Future 
studies need to investigate potential laterality differences 
in the application of rTMS or iTBS. Given the results, it is 
difficult to determine mediating neurobiological factors. 
From the available literature (see ‘Introduction’) a posi-
 2   When dropouts were excluded and only the remaining participants in-
cluded in the further analyses, the results stayed the same.









Age, years 46.74 ± 10.08 46.32 ± 9.48 n.s.
Male gender, n 16 24 n.s.
Age when started smoking, 
years 17.13 ± 3.59 17.94 ± 4.37 n.s.
Age at first cigarette, years 15.00 ± 2.85 15.47 ± 2.94 n.s.
Cigarettes/day, n 21.67 ± 5.14 22.89 ± 6.58 n.s.
Attempts to quit, n 2.13 ± 1.82 3.24 ± 4.64 n.s.1
Smoking, years 28.63 ± 11.16 27.35 ± 7.51 n.s.1
FTND 5.00 ± 1.61 4.75 ± 1.63 n.s.
 Values are given as mean ± SD.
1 Given the large difference in variance between the groups, 
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tive modulation of prefrontal structures or neural circuits 
that involve these structures might be assumed, but this 
needs to be confirmed in systematic neurobiological 
studies.
 Questionnaire data did not reveal any additional ben-
efits of iTBS. General improvements across the groups 
could be shown. The QSU indicated the expected reduc-
tion in craving, which is the primary aim of CBT. This was 
accompanied by changes in the SER, which indicates in-
creased confidence of staying abstinent and decreased 
temptation to smoke. Most likely, these results can be as-
cribed to CBT; however, a small moderating or additive 
effect with iTBS in other variables than those assessed in 
the present study cannot be ruled out.
 Although the results of add-on iTBS are promising, 
several caveats have to be considered. First, the presented 
data are the results of a pilot study in which certain as-
pects were not systematically assessed, e.g. objective ab-
stinence (CO levels), number of cigarettes smoked per 
day/week by relapsers, or use of nicotine replacement 
products. Second, follow-up telephone interviews may 
reduce data accuracy and reliability. Objective measures 
(e.g. breath CO, urine or saliva cotinine) could circum-
vent potential biases of retrospective self-report. Third, 
participants were TMS-naïve and blind to group assign-
ment; yet, it cannot be ruled out that they might have hy-
pothesized about it. However, posttreatment interroga-
tion of assumed group assignment indicated actual blind-
ness. Consistently, Herwig et al.  [43] showed that TMS 
novices could not distinguish rTMS treatment from sham 
rTMS. Fourth, dropouts were increasing over time and 
differed between the groups at 12 months, which should 
be interpreted cautiously; labeling dropouts as relapsing 
participants may not reflect reality and bias the results 
(however, see footnote 2). Fifth, although we were cor-
rectly applying hypothesis-driven one-sided testing, it 
needs to be stated that two-sided testing only results in a 
trend effect. Nonetheless, given this study’s pilot charac-
ter and including power aspects (i.e. balancing type I and 
type II error) to detect potential effects of such a modern 
add-on therapy, we consider even a trend effect an impor-
tant finding. Sixth, 4 sessions of iTBS may not be suffi-
cient to enable longer-lasting effects; especially when 
treatment time is restricted, offering booster sessions af-
ter a specific interval may be an available option. Such 
sessions could be accompanied by additional CBT group 
 Table 2.  Group statistics for the investigated questionnaires
Questionnaire  iTBS treatment (n = 38) Sham iTBS (n = 36) Statistics
pre po st pre post
SER temptation 75.08 ± 13.91 46.32 ± 18.93 76.31 ± 13.52 45.39 ± 16.85 F1, 72 = 212.32*
SER confidence 54.03 ± 15.84 72.95 ± 19.25 54.94 ± 16.32 73.72 ± 19.05 F1, 72 = 48.95*
QSU 83.63 ± 36.79 56.5 ± 33.78 81.89 ± 35.88 47.66 ± 16.65 F1, 70 = 61.28*
 pre = Pretreatment (prior to CBT meeting 1); post = posttreatment. Values are given as mean ± SD; * p < 0.001. 
 Table 3.  Descriptive statistics for the abstinence data in the two treatment groups
iTBS treatment (n = 38)  Sham iTBS (n = 36) Statistics
OR (95% CI)abstinent relapse1 absti nent relapse1
3 months 19 19 (9) 10 26 (12) 2.60 (1.15, 5.86)*
6 months 12 26 (12) 10 26 (16) 1.20 (0.52, 2.78)
12 months 10 28 (19) 5 31 (25) 2.21 (0.82, 6.01)
 OR = Odds ratio.
1 Participants for whom information was not available were counted as dropouts (given in parentheses; as 
dropout was not randomly distributed between groups at month 12, results cannot be interpreted and are only 
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meetings to consolidate effects and increase relapse pre-
vention. Seventh, we regarded craving the crucial mediat-
ing factor in achieving abstinence. However, changes in 
craving did not differ between groups, indicating that 
craving was not a substantial mediator between iTBS and 
abstinence in our study. Unlike reduced craving follow-
ing rTMS of the right dlPFC  [20, 21] , the expected pro-
cesses could not be shown after iTBS. It may be that dif-
ferent neurobiological processes are triggered in the two 
protocols, which influence addictive behavior; this ques-
tion, however, will have to be addressed in more basic 
research studies.
 To summarize, despite the above-mentioned limita-
tions that should not be neglected, this pilot study reports 
for the first time a possible effect of an iTBS protocol in 
aiding smoking cessation. Further studies are needed to 
answer the currently unresolved open questions.
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